Curated News
By: NewsRamp Editorial Staff
July 03, 2025
Nutriband and Kindeva Achieve Key Milestone in Opioid Safety Innovation
TLDR
- Nutriband's AVERSA Fentanyl completion and analyst upgrade to $15.00 target offers investors a strategic advantage in the biotech sector.
- Nutriband and Kindeva have scaled up commercial manufacturing for AVERSA Fentanyl, marking a critical step towards FDA approval and market entry.
- AVERSA's abuse-deterrent technology represents a significant advancement in safe pain management, potentially reducing opioid abuse and saving lives globally.
- Nutriband joins the Russel Indexes, elevating its profile while pioneering in the fight against the opioid crisis with innovative technology.
Impact - Why it Matters
The development of AVERSA(TM) Fentanyl by Nutriband and Kindeva is a critical advancement in the fight against the opioid crisis, offering a safer alternative for pain management. This innovation not only has the potential to reduce abuse and addiction rates but also addresses a significant unmet need in healthcare, impacting patients, healthcare providers, and policymakers worldwide. The progress towards FDA approval and the positive analyst outlook underscore the importance of this breakthrough in a sector desperate for solutions.
Summary
Nutriband Inc. (NASDAQ: NTRB) and Kindeva Drug Delivery have achieved a significant milestone by completing the commercial-scale manufacturing process for AVERSA(TM) Fentanyl, marking a pivotal step towards FDA approval. This development is underscored by an updated analyst report that raises Nutriband's price target to $15.00, reaffirming an Outperform rating due to its promising trial pathway and effective execution. AVERSA's abuse-deterrent technology, safeguarded by international patents, presents a potential solution to the global challenge of safe pain management amidst the opioid crisis. Additionally, Nutriband's inclusion in the Russel Indexes enhances its market profile and credibility.
The collaboration between Nutriband and Kindeva highlights the urgent need for innovative approaches to opioid safety, as detailed in a feature on BioMedWire. This news is particularly relevant as the opioid crisis continues to demand solutions that balance effective pain management with public safety concerns. Nutriband's progress with AVERSA(TM) Fentanyl could represent a turning point in addressing these dual challenges.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband and Kindeva Achieve Key Milestone in Opioid Safety Innovation
